{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:45:22Z","timestamp":1791251122078,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,21]]},"DOI":"10.7759\/cureus.111227","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T12:06:47Z","timestamp":1782043607000},"source":"Crossref","is-referenced-by-count":1,"title":["Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies"],"prefix":"10.7759","author":[{"given":"Abdulaziz","family":"Alroshodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin BH","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al.. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021, 100:S1-276. 10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler DC","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al.. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021, 100:215-24. 10.1016\/j.kint.2021.03.033","journal-title":"Kidney Int"},{"key":"ref3","unstructured":"US Food and Drug Administration. FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. (2022). https.\/\/www.fda.gov\/drugs\/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease.."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin BH","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJ, et al.. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023, 402:2077-90. 10.1016\/S0140-6736(23)02302-4","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang H","year":"2024","unstructured":"Zhang H, Rizk DV, Perkovic V, et al.. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024, 105:189-99. 10.1016\/j.kint.2023.09.027","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette RA","year":"2020","unstructured":"Lafayette RA, Rovin BH, Reich HN, Tumlin JA, Floege J, Barratt J. Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy. Kidney Int Rep. 2020, 5:2032-41. 10.1016\/j.ekir.2020.08.003","journal-title":"Kidney Int Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur M","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al.. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024, 390:20-31. 10.1056\/NEJMoa2305635","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.92a.24105","article-title":"IgA nephropathy: update on pathogenesis and treatment","volume":"92","author":"Ramsawak S","year":"2025","unstructured":"Ramsawak S, Cohen S, Linares A, Cavanaugh C. IgA nephropathy: update on pathogenesis and treatment. Cleve Clin J Med. 2025, 92:373-83. 10.3949\/ccjm.92a.24105","journal-title":"Cleve Clin J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2025.151573","article-title":"The rapidly changing treatment landscape of IgA nephropathy","volume":"44","author":"Cheung CK","year":"2024","unstructured":"Cheung CK, Barratt J. The rapidly changing treatment landscape of IgA nephropathy. Semin Nephrol. 2024, 44:151573. 10.1016\/j.semnephrol.2025.151573","journal-title":"Semin Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cdt3.104","article-title":"Advances in the treatment of IgA nephropathy with biological agents","volume":"10","author":"Zhuang Y","year":"2024","unstructured":"Zhuang Y, Lu H, Li J. Advances in the treatment of IgA nephropathy with biological agents. Chronic Dis Transl Med. 2024, 10:1-11. 10.1002\/cdt3.104","journal-title":"Chronic Dis Transl Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/978-4-431-55588-9_9","article-title":"Prognostic Indicators and Treatment of IgA Nephropathy in China","author":"Le WB","year":"2016","unstructured":"Le WB, Liu ZH. Prognostic Indicators and Treatment of IgA Nephropathy in China. Pathogenesis and Treatment in IgA Nephropathy. Tomino Y (ed): Springer, Tokyo, Japan; 2016. 127-39. 10.1007\/978-4-431-55588-9_9"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae151","article-title":"The use of albuminuria or proteinuria for risk prediction in IgAN","volume":"40","author":"Cheung CK","year":"2024","unstructured":"Cheung CK, Barratt J. The use of albuminuria or proteinuria for risk prediction in IgAN. Nephrol Dial Transplant. 2024, 40:1-3. 10.1093\/ndt\/gfae151","journal-title":"Nephrol Dial Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.05.064","article-title":"Epidemiology and risk factors for progression in Chinese patients with IgA nephropathy","volume":"157","author":"Liu Y","year":"2021","unstructured":"Liu Y, Wei W, Yu C, et al.. Epidemiology and risk factors for progression in Chinese patients with IgA nephropathy. Med Clin (Barc). 2021, 157:267-73. 10.1016\/j.medcli.2020.05.064","journal-title":"Med Clin (Barc)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000530341","article-title":"Current status and perspectives on recurrent IgA nephropathy after kidney transplantation","volume":"147","author":"Kawabe M","year":"2023","unstructured":"Kawabe M, Yamamoto I. Current status and perspectives on recurrent IgA nephropathy after kidney transplantation. Nephron. 2023, 147:9-13. 10.1159\/000530341","journal-title":"Nephron"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30310-8","article-title":"Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population","volume":"6","author":"Covic A","year":"2018","unstructured":"Covic A, Vervloet M, Massy ZA, et al.. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol. 2018, 6:319-31. 10.1016\/S2213-8587(17)30310-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000134","article-title":"Pathophysiology of IgA nephropathy","volume":"24","author":"Al Hussain T","year":"2017","unstructured":"Al Hussain T, Hussein MH, Al Mana H, Akhtar M. Pathophysiology of IgA nephropathy. Adv Anat Pathol. 2017, 24:56-62. 10.1097\/PAP.0000000000000134","journal-title":"Adv Anat Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwae060","article-title":"O-glycosylation of IgA1 and the pathogenesis of an autoimmune disease IgA nephropathy","volume":"34","author":"Novak J","year":"2024","unstructured":"Novak J, King RG, Yother J, Renfrow MB, Green TJ. O-glycosylation of IgA1 and the pathogenesis of an autoimmune disease IgA nephropathy. Glycobiology. 2024, 34:10.1093\/glycob\/cwae060","journal-title":"Glycobiology"},{"key":"ref18","article-title":"The Role of Glycosylation Initiation by GalNAc-Ts in IgA Nephropathy (Doctoral Dissertation)","author":"Stewart TJ","year":"2018","unstructured":"Stewart TJ. The Role of Glycosylation Initiation by GalNAc-Ts in IgA Nephropathy (Doctoral Dissertation). University of Alabama at Birmingham, United Kingdom; 2018."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70382","article-title":"Immunoglobulin A nephropathy: molecular pathogenesis and targeted therapy","volume":"6","author":"Zhou XJ","year":"2025","unstructured":"Zhou XJ. Immunoglobulin A nephropathy: molecular pathogenesis and targeted therapy. MedComm (2020). 2025, 6:e70382. 10.1002\/mco2.70382","journal-title":"MedComm (2020)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128393","article-title":"Molecular insight in intrarenal inflammation affecting four main types of cells in nephrons in IgA nephropathy","volume":"10","author":"Zhang H","year":"2023","unstructured":"Zhang H, Deng Z, Wang Y. Molecular insight in intrarenal inflammation affecting four main types of cells in nephrons in IgA nephropathy. Front Med (Lausanne). 2023, 10:1128393. 10.3389\/fmed.2023.1128393","journal-title":"Front Med (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246336","article-title":"Complement and complement targeting therapies in glomerular diseases","volume":"20","author":"Andrighetto S","year":"2019","unstructured":"Andrighetto S, Leventhal J, Zaza G, Cravedi P. Complement and complement targeting therapies in glomerular diseases. Int J Mol Sci. 2019, 20:10.3390\/ijms20246336","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui K","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024, 35:103-16. 10.1681\/ASN.0000000000000242","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-019-01700-1","article-title":"New strategies and perspectives on managing IgA nephropathy","volume":"23","author":"Selvaskandan H","year":"2019","unstructured":"Selvaskandan H, Cheung CK, Muto M, Barratt J. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019, 23:577-88. 10.1007\/s10157-019-01700-1","journal-title":"Clin Exp Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000306","article-title":"Optimal conservative therapy use among adult cure glomerulonephropathy participants with IgA nephropathy","volume":"4","author":"Rajasekaran A","year":"2023","unstructured":"Rajasekaran A, Larkina M, Julian BA, et al.. Optimal conservative therapy use among adult cure glomerulonephropathy participants with IgA nephropathy. Kidney360. 2023, 4:1763-9. 10.34067\/KID.0000000000000306","journal-title":"Kidney360"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2174\/1573402116666200615152139","article-title":"Potential novel benefits of sodium restriction in chronic kidney disease","volume":"17","author":"Valtuille R","year":"2021","unstructured":"Valtuille R. Potential novel benefits of sodium restriction in chronic kidney disease. Curr Hypertens Rev. 2021, 17:59-66. 10.2174\/1573402116666200615152139","journal-title":"Curr Hypertens Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/nu12071931","article-title":"Plant-dominant low-protein diet for conservative management of chronic kidney disease","volume":"12","author":"Kalantar-Zadeh K","year":"2020","unstructured":"Kalantar-Zadeh K, Joshi S, Schlueter R, et al.. Plant-dominant low-protein diet for conservative management of chronic kidney disease. Nutrients. 2020, 12:10.3390\/nu12071931","journal-title":"Nutrients"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IGAV)","volume":"108","author":"Rovin BH","year":"2025","unstructured":"Rovin BH, Barratt J, Cook HT, et al.. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IGAV). Kidney Int. 2025, 108:S1-71. 10.1016\/j.kint.2025.04.004","journal-title":"Kidney Int"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20223311S1502e","article-title":"Prevalence of optimal conservative therapy implementation among CureGN participants with IgA nephropathy: Fr-Po657","volume":"33","author":"Rajasekaran A","year":"2022","unstructured":"Rajasekaran A, Larkina M, Julian BA, Mariani LH, Rizk D. Prevalence of optimal conservative therapy implementation among CureGN participants with IgA nephropathy: Fr-Po657. J Am Soc Nephrol. 2022, 33:502-3.","journal-title":"J Am Soc Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomized controlled trial","volume":"353","author":"Pozzi C","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, et al.. Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancet. 1999, 353:883-887. 10.1016\/S0140-6736(98)03563-6","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.03.032","article-title":"The efficacy and safety of reduced-dose oral methylprednisolone in high-risk immunoglobulin A nephropathy","volume":"9","author":"Kim D","year":"2024","unstructured":"Kim D, Lv J, Hladunewich M, et al.. The efficacy and safety of reduced-dose oral methylprednisolone in high-risk immunoglobulin A nephropathy. Kidney Int Rep. 2024, 9:2168-79. 10.1016\/j.ekir.2024.03.032","journal-title":"Kidney Int Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1159\/000487265","article-title":"IgA nephropathy: a European perspective in the corticosteroid treatment","volume":"4","author":"Coppo R","year":"2018","unstructured":"Coppo R. IgA nephropathy: a European perspective in the corticosteroid treatment. Kidney Dis (Basel). 2018, 4:58-64. 10.1159\/000487265","journal-title":"Kidney Dis (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen T","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, et al.. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015, 373:2225-36. 10.1056\/NEJMoa1415463","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02644-2","article-title":"Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria","volume":"53","author":"Zhong Z","year":"2021","unstructured":"Zhong Z, Tang Y, Tan J, Tan L, Pei G, Qin W. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria. Int Urol Nephrol. 2021, 53:121-7. 10.1007\/s11255-020-02644-2","journal-title":"Int Urol Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-024-01438-3","article-title":"Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy: a systematic review and meta-analysis","volume":"24","author":"Zhang D","year":"2024","unstructured":"Zhang D, Xia B, Zhang X, Liang P, Hu X. Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy: a systematic review and meta-analysis. BMC Urol. 2024, 24:56. 10.1186\/s12894-024-01438-3","journal-title":"BMC Urol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar V","year":"2015","unstructured":"Tesar V, Troyanov S, Bellur S, et al.. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol. 2015, 26:2248-2258. 10.1681\/ASN.2014070697","journal-title":"J Am Soc Nephrol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","volume":"16","author":"Fern\u00e1ndez-Fernandez B","year":"2023","unstructured":"Fern\u00e1ndez-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023, 16:1187-98. 10.1093\/ckj\/sfad082","journal-title":"Clin Kidney J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/03000605251376895","article-title":"Effect of dapagliflozin on proteinuria and the slope of the estimated glomerular filtration rate in patients with immunoglobulin A nephropathy: a multicenter prospective study","volume":"53","author":"Koshida T","year":"2025","unstructured":"Koshida T, Suzuki H, Murkoashi M, Takahara H, Suzuki Y, Gohda T. Effect of dapagliflozin on proteinuria and the slope of the estimated glomerular filtration rate in patients with immunoglobulin A nephropathy: a multicenter prospective study. J Int Med Res. 2025, 53:3000605251376895. 10.1177\/03000605251376895","journal-title":"J Int Med Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.1334","article-title":"Relationship between initial eGFR dip with proteinuria after SGLT2i treatment in patients with IgA nephropathy: a real-world clinical study","volume":"39","author":"Xydakis D","year":"2024","unstructured":"Xydakis D, Antonaki E, Tzali E, et al.. Relationship between initial eGFR dip with proteinuria after SGLT2i treatment in patients with IgA nephropathy: a real-world clinical study. Nephrol Dial Transplant. 2024, 39:069-1334. 10.1093\/ndt\/gfae069.1334","journal-title":"Nephrol Dial Transplant"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink HJ","year":"2023","unstructured":"Heerspink HJ, Radhakrishnan J, Alpers CE, et al.. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023, 401:1584-94. 10.1016\/S0140-6736(23)00569-X","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae394","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"18","author":"Schanz M","year":"2025","unstructured":"Schanz M, Seikrit C, Hohenstein B, et al.. First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors. Clin Kidney J. 2025, 18:sfae394. 10.1093\/ckj\/sfae394","journal-title":"Clin Kidney J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette R","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, et al.. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023, 402:859-70. 10.1016\/S0140-6736(23)01554-4","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege J","year":"2025","unstructured":"Floege J, Lafayette R, Barratt J, et al.. Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy. Kidney Int. 2025, 108:695-706. 10.1016\/j.kint.2025.05.028","journal-title":"Kidney Int"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61122233","article-title":"Comparative efficacy and safety of pharmacological interventions for IgA nephropathy: a systematic review and meta-analysis","volume":"61","author":"Alroshodi A","year":"2025","unstructured":"Alroshodi A, Al-Harbi FA, Alkuwaiti MA, et al.. Comparative efficacy and safety of pharmacological interventions for IgA nephropathy: a systematic review and meta-analysis. Medicina (Kaunas). 2025, 61:10.3390\/medicina61122233","journal-title":"Medicina (Kaunas)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1515723","article-title":"Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials","volume":"12","author":"Chen B","year":"2025","unstructured":"Chen B, Zhu Y, Yang Y, Xu G. Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials. Front Med (Lausanne). 2025, 12:1515723. 10.3389\/fmed.2025.1515723","journal-title":"Front Med (Lausanne)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47393-1","article-title":"An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression","volume":"13","author":"Obri\u0219c\u0103 B","year":"2023","unstructured":"Obri\u0219c\u0103 B, Vornicu A, Mocanu V, et al.. An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression. Sci Rep. 2023, 13:20119. 10.1038\/s41598-023-47393-1","journal-title":"Sci Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S389456","article-title":"Cost-effectiveness analysis of Nefecon versus best supportive care for people with immunoglobulin A nephropathy (IgAN) in the United States","volume":"15","author":"Ramjee L","year":"2023","unstructured":"Ramjee L, Vurgun N, Ngai C, Patel M, Tremblay G. Cost-effectiveness analysis of Nefecon versus best supportive care for people with immunoglobulin A nephropathy (IgAN) in the United States. Clinicoecon Outcomes Res. 2023, 15:213-26. 10.2147\/CEOR.S389456","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.1327","article-title":"IONIS-FB-LRx, an antisense oligonucleotide to complement factor B for treatment of IgA nephropathy","volume":"39","author":"Hladunewich M","year":"2024","unstructured":"Hladunewich M, Barbour S, Makris A, et al.. IONIS-FB-LRx, an antisense oligonucleotide to complement factor B for treatment of IgA nephropathy. Nephrol Dial Transplant. 2024, 39:1327. 10.1093\/ndt\/gfae069.1327","journal-title":"Nephrol Dial Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493073-recent-advances-in-the-management-of-iga-nephropathy-from-supportive-care-to-targeted-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T12:06:49Z","timestamp":1782043609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493073-recent-advances-in-the-management-of-iga-nephropathy-from-supportive-care-to-targeted-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.111227","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,21]]}}}